Evidence map›Paper›PMID 41408353›Full record

ArticleGlobal health research and policy2025

Predicting benign prostatic hyperplasia risks: model development and external validation based on three cohorts.

Hao Zi, Yong-Bo Wang, Qiao Huang, Yuan-Yuan Zhang, Fa-Zhi He, Li-Min Xing, Yan Yao, Bing-Hui Li, Li-Sha Luo, Fei Li and 3 more

Abstract readValidation Study
In one paragraph

Article in Global health research and policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hao Zi *Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yong-Bo Wang *Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Qiao HuangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yuan-Yuan ZhangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Fa-Zhi HeSchool of Computer Science, Wuhan University, Wuhan, China.
Li-Min XingDepartment of Physical Examination, Integrated Chinese and Western Medicine Hospital of XiangYang (Dongfeng People's Hospital), Xiangyang, China.
Yan YaoDepartment of Physical Examination, Integrated Chinese and Western Medicine Hospital of XiangYang (Dongfeng People's Hospital), Xiangyang, China.
Bing-Hui LiCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Li-Sha LuoCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Fei LiCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Shi-Di TangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xian-Tao ZengCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. zengxiantao1128@whu.edu.cn.ORCID http://orcid.org/0000-0003-1262-725X
Jiao HuangCenter for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. huangjiao1019@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs benign prostatic hyperplasia (BPH) becomes increasingly prevalent, there is a growing need for simple and accurate methods to predict its risk. This study aimed to develop and validate a prediction model to identify males at high risk of developing BPH.

methodsThe model was developed using data from 210,408 participants in the UK Biobank and externally validated with 5394 participants from the China Health and Retirement Longitudinal Study (CHARLS) and 294 participants from the Fengshen study. Six methods were employed to construct prediction models utilizing readily available medical characteristics at baseline. The DeLong tests were used to assess the differences in the area under the curves (AUCs). Cox regression was adopted to examine the relationships between the predictors and BPH.

resultsDuring a median follow-up period of 13.2 years (interquartile range [IQR] 12.3-14.0), 7.0 years (IQR 6.8-7.0) and 4.0 years (IQR 2.2-5.0), 18,681 males in the UK Biobank, 309 males in the CHARLS, and 27 males in the Fengshen study developed BPH. The model developed using the LightGBM method exhibited the highest discriminative capability among the six methods. Following feature reduction based on importance ranking, a full model with 17 predictors was established for BPH prediction (AUC = 0.688 ± 0.004). Age was the most important feature that contributed to the model, with older males showing a higher hazard ratio (HR) of 1.091 (95% confidence interval [CI] 1.089-1.094) for BPH incidence. Furthermore, a final simplified model was developed using five predictors (age, hypertension time, blood glucose, urate, and serum creatinine) identified in both the CHARLS and Fengshen studies for potential clinical application. It has been transformed into a user-friendly web tool to facilitate clinical utility.

conclusionsThe model, incorporating five easily accessible predictors with acceptable predictive abilities for incident BPH, can help identify individuals at high risk of BPH in the general population.

Indexed as

Prostatic HyperplasiaAgedChinaHumansLongitudinal StudiesMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsUnited KingdomBenign prostatic hyperplasiaIncidenceMachine learningPrediction model

Identifiers

PMID41408353
PMCPMC12709829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.